Ultragenyx And Mereo BioPharma Report Data From Ongoing Phase 2/3 Orbit Study Of Setrusumab (UX143) In Osteogenesis Imperfecta (OI)
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx and Mereo BioPharma report positive data from the ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI). The treatment showed significant improvements in bone formation and density, with no serious adverse events observed.
June 05, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mereo BioPharma's ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) shows positive results, with significant improvements in bone formation and density.
The positive results from the ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) indicate that the treatment is effective and safe. This is likely to have a positive impact on Mereo BioPharma's stock price in the short term as it demonstrates the potential success of the treatment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 50
POSITIVE IMPACT
Ultragenyx's ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) shows positive results, with significant improvements in bone formation and density.
The positive results from the ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) indicate that the treatment is effective and safe. This is likely to have a positive impact on Ultragenyx's stock price in the short term as it demonstrates the potential success of the treatment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 50